SEC Form 4 · accession 0002150331-26-000002
Lyell Immunopharma, Inc. · LYEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jarrad Mattieu Aguirre
Officer — Chief Medical Officer
Period of report
Sep 10, 2026
Accepted (ET)
Sep 10, 2026 · 7:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001806952
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 20,279 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2 | $12.20 | Sep 10, 2026 | A | 47,500 | A | — | Sep 9, 2036 | Common Stock | 47,500 | 47,500 | D |
Explanation of responses
- F1Includes 14,451 restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting and will be settled in common stock subject to vesting as follows: the RSUs vest quarterly over the thirty month period following July 9, 2026; in each case, subject to the reporting person providing service through the applicable vesting date.
- F212.5% of the option shares will vest on February 28, 2027, with the remaining option shares to vest in equal monthly installments over the following 42 months, subject to the reporting person providing service through the applicable vesting date.